Cystoid macular oedema in Cogans syndrome-a case report
© Pherwani et al; licensee BioMed Central Ltd. 2008
Received: 21 May 2008
Accepted: 20 November 2008
Published: 20 November 2008
Cogan's Syndrome is typically characterised by a non syphilitic interstitial keratitis (IK), with or without conjunctivitis, iritis or subconjunctival bleeding and progressive sensorineural hearing loss within two years of ocular signs. Atypical ocular manifestations include episcleritis, scleritis, posterior scleritis, retinal artery occlusion, choroiditis, retinal vasculitis, and optic disc oedema. We report a case of Cogan's syndrome in with recurrent cystoid macular oedema was the main feature.
A patient was diagnosed with Cogan's syndrome nearly 2 years after first presentation. He had cystoid macular edema which failed to respond initially to steroid, methotrexate and azothiaprine however resolved after treatment with mycophenolate mofetil.
Cogan's syndrome is rare and presents a challenge in terms of diagnosis and treatment. Recurrent cystoid macular oedema is a unique finding in this condition and can be difficult to control. Multidisciplinary management of this multisystem disorder is vital.
David Cogan first described typical Cogan's syndrome in 1945. It presents with non syphilitic interstitial keratitis (IK), with or without conjunctivitis, iritis or subconjunctival bleeding and Menier's like audiovestibular signs associated with progressive sensorineural hearing loss within two years of ocular signs  Atypical Cogan's encompasses other ocular or audiovestibular symptoms or a delay of more than 2 years between them . Atypical ocular manifestations include episcleritis, scleritis, posterior scleritis, retinal artery occlusion, choroiditis, retinal vasculitis, and optic disc oedema with or without IK [3, 4]
Cystoid macular edema (CMO) in Cogan's syndrome has not been described before. Vollertsen et al in their review report macular involvement, but do not describe the pathology seen at the macula . We report a case of Cogan's syndrome in which recalcitrant CMO was the main feature.
A 54 year old Caucasian man presented to eye casualty with a history of blurred vision and grittiness in his right eye (RE) for over six months. Snellen visual acuity was 6/5 in both eyes. Examination revealed mild injection and a stromal opacity with deep vascularisation in the superior aspect of the right cornea. There was no associated inflammation in the anterior chamber and corneal sensation was normal. Examination of the left eye was unremarkable. A diagnosis of probable non necrotising herpetic stromal keratitis was made and the eye treated with topical prednisolone acetate 0.5%. Three weeks later, the patient was asymptomatic and the injection had resolved. The topical treatment was tapered and discontinued.
The patient, re-attended 3 months later with similar symptoms along with acute onset tinnitus in the right ear and deafness of 3 weeks duration. Ocular examination revealed the corneal stromal opacity, which was now diagnosed as interstitial keratitis. There were no signs of active inflammation in the eye. Blood tests were performed and a high ESR (88 mm at 1 hour) was the only positive finding. All autoantibodies including ANA, cANCA, pANCA were negative, serum ACE was within normal limits, no antibodies were found against treponema pallidum and borrelia bergdorfi. The patient was referred to an otorhinologist, who performed an audiogram, which revealed bilateral sensorineural deafness.
A diagnosis of Cogan's syndrome was made after taking into account the history, clinical findings and results of investigations. The visual acuity over the next 2 weeks deteriorated to 6/18 in the RE and 6/12 in the LE. Oral Prednisolone (40 mg/day) was commenced as treatment. The CMO resolved and hearing improved 2 weeks following treatment. However, once Prednisolone was tapered to 10 mg per day, the CMO recurred. Over a period of 1 year, the CMO fluctuated in severity inversely to the dose of steroids. Triamcinolone acetonide (40 mg) was injected into the orbital floor on two occasions with no benefit. The patient developed secondary posterior subcapsular cataract in the RE and steroid induced diabetes mellitus. He was therefore commenced on intramuscular methotrexate. The CMO did not respond to methotrexate, this was therefore substituted with Azathioprine 125 mg daily. The patient was intolerant to the azathioprine and was commenced on Mycophenolate mofetil. CMO finally settled with Mycophenolate mofetil which enabled tapering off the oral steroid. There was no further deterioration of vision and no recurrence of CMO over 6 months with snellen visual acuity stabilising at 6/24 in the RE (6/12 with pinhole) and 6/9 in the LE.
Cogan's syndrome is a rare auto immune disorder with ocular, auditory and systemic manifestations. It appears to occur in young adult Caucasians of either sex. The ocular involvement is variable, usually bilateral and can cause moderate to severe visual loss. Vollertsen et al reported blindness in 8 out of 156 eyes, with bilateral loss of vision in 2 patients .
The disease course of Cogan's syndrome may vary with some patients experiencing an initial flare lasting weeks or months followed by slow progression, whilst others display recurrent ocular or vestibular flare ups. Permanent deafness and death due to systemic manifestations may also occur.
The aetiology and pathogenesis of Cogan's syndrome is unclear. An autoimmune basis has been suggested with description of autoantibodies against the inner ear and endothelium . Diagnosis however is based on clinical findings and history.
Corticosteroids are the first line of treatment and it is argued that if given early in the disease course can aid recovery of the hearing. Immunosupressive drugs like methotrexate, azathioprine, cyclosporine and cyclophosphamide have all been tried with varying degree of success [7–10]. However in the absence of controlled trials, there are no definitive therapeutic recommendations.
This case highlights the variability of presentation of this rare syndrome and to our knowledge is the first described case of Cogan's syndrome with recurring cystoid macular oedema. Delay in diagnosis is common and can lead to visual and auditory disability. It is a multisystem disease, which can be sight threatening and aggressive therapeutic intervention may be needed to control the ocular pathology and prevent visual loss. Optimum management of these patients needs close co-operation of the ophthalmologist, otorhinolaryngologist and physician.
The authors obtained written informed consent from the parents of this patient for the publication of this case report along with images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Cogan DG: Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol. 1945, 33: 144-9.View ArticleGoogle Scholar
- Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS: Cogan syndrome: studies in thirteen patients, long-term follow up and a review of the literature. Medicine. 1980, 59: 426-41. 10.1097/00005792-198011000-00003.View ArticlePubMedGoogle Scholar
- Grasland A, Pouchot J, Hachulla E, Bletry O: Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology. 2004, 43 (8): 1007-1015. 10.1093/rheumatology/keh228.View ArticlePubMedGoogle Scholar
- Shah P, Luqmani RA, Murray PI, Honan WP: Posterior scleritis. An unusual manifestation of Cogan's syndrome. Br J Rheumatol. 1994, 33: 774-5. 10.1093/rheumatology/33.8.774.View ArticlePubMedGoogle Scholar
- Vollertsen RS, McDonald TJ, Younge BR, Banks PM: Cogan's syndrome:18 cases and a review of the literature. Mayo Clin Proc. 1986, 61: 344-61.View ArticlePubMedGoogle Scholar
- Helmchen C, Arbusow V, Jager L: Cogan's syndrome: clinical significance of antibodies against inner ear and cornea. Acta Otolaryngol. 1999, 119: 528-37. 10.1080/00016489950180748.View ArticlePubMedGoogle Scholar
- Allen B, Cox CC, Cobo M: Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. Am J Med. 1990, 88: 296-301. 10.1016/0002-9343(90)90157-9.View ArticlePubMedGoogle Scholar
- Richardson B: Methotrexate therapy for hearing loss in Cogan's syndrome. Arthritis Rheum. 1994, 37: 1559-61. 10.1002/art.1780371026.View ArticlePubMedGoogle Scholar
- Riente L, Taglione E, Berrettini S: Efficacy of methotrexate in Cogan's Syndrome. J Rheumatol. 1996, 23: 1830-1.PubMedGoogle Scholar
- Roat MI, Thoft RA, Thompson AW, Jain A: Treatment of Cogan's syndrome with FK506: a case report. Transplant Proc. 1991, 23 (6): 3347.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.